Condition
Pancreatic Neuroendocrine Neoplasm
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Recruiting3
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06202066Phase 2Recruiting
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
NCT05746182RecruitingPrimary
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms
NCT06592989RecruitingPrimary
A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET
NCT05316480Phase 2Not Yet RecruitingPrimary
Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
Showing all 4 trials